摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine | 121588-66-7

中文名称
——
中文别名
——
英文名称
(+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine
英文别名
(2S,6S)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-triene-4,9-dione
(+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine化学式
CAS
121588-66-7
化学式
C17H17NO4
mdl
——
分子量
299.326
InChiKey
FTDKWACFCUDDKI-GUYCJALGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    22
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • A Formal Total Synthesis of (±)-Cephalotaxine Using Sequential <i>N</i>-Acyliminium Ion Reactions
    作者:Yuji Koseki、Hiroto Sato、Yumi Watanabe、Tatsuo Nagasaka
    DOI:10.1021/ol017114f
    日期:2002.3.1
    [reaction: see text] Novel synthesis of cephalotaxine 1 based on tertiary N-acyliminium ion chemistry starting from alkynylamide 2 was achieved. The key steps include the preparation of pyrroloisoquinoline 4 from alkynylamide 2, the ring expansion of pyrroloisoquinoline 4 to pyrrolobenzazepine 12, and the construction of cyclopentapyrrolobenzazepine ring system 6, all of which are derived from N-acyliminium
    [反应:见正文]从叔乙酰胺2开始,基于叔N-嘧啶离子化学合成了头孢他辛1。关键步骤包括从炔基酰胺2制备吡咯并异喹啉4,吡咯并异喹啉4到吡咯并苯并enza庚因12的扩环以及环戊吡咯并并苯并氮杂卓环体系6的构建,所有这些均来自N-酰基酰亚胺离子中间体。
  • 一种三尖杉碱骨架E环的不对称合成方法
    申请人:河北科技大学
    公开号:CN107903276B
    公开(公告)日:2019-09-17
    本发明涉及一种三尖杉碱中间体的催化不对称合成方法,以10,10a‑二氢‑5H‑[1,3]二氧杂环戊烯并[4',5':4,5]苯并[1,2‑d]吡咯并[1,2‑a]氮杂‑8,11‑(6H,9H)‑二酮N为原料,经过酮的烯醇氧原子的酯化反应、分子内不对称脱羧烯丙基化、Wacker氧化、Aldol缩合、选择性催化加氢和可见光与Ag/TiO2和萨伦锰(salen‑Mn)共催化空气氧化得到关键的手性中间体(11bS,12S,14aS)‑12‑羟基‑13,13‑二甲氧基‑5,6,11b,12,13,14‑六氢‑1H‑[1,3]二氧杂环戊烯并[4',5':4,5]苯并[1,2‑d]环戊烷并[b]吡咯并[1,2‑a]氮杂‑3(2H)‑酮T,产物的ee值最高可达99%。相较于文献上的以手性化合物为起始原料的不对称合成,此方法成本较低,催化效率较高,六步合成E环关键中间体T的总收率为51.8%,具有较好的工业化前景。
  • Asymmetric Formal Synthesis of (−)-Cephalotaxine via Palladium-Catalyzed Enantioselective Tsuji Allylation
    作者:Zhi-Wei Zhang、Cui-Cui Wang、Hong Xue、Yu Dong、Jian-Hua Yang、Shouxin Liu、Wen-Qing Liu、Wei-Dong Z. Li
    DOI:10.1021/acs.orglett.7b04008
    日期:2018.2.16
    Asymmetric synthesis of the pentacyclic alkaloid ()-cephalotaxine was accomplished via palladium-catalyzed enantioselective Tsuji allylation for construction of the aza-containing tetrasubstituted stereogenic center (95% yield, 93% ee). The allyl enol carbonate precursor was prepared from Hanaoka’s ketone intermediate, which was formed by a novel formic acid promoted ring-expansion reaction.
    五环生物碱(-)-头孢他辛的不对称合成是通过钯催化的对映选择性Tsuji烯丙基化反应完成的,用于构建含氮杂的四取代立体异构中心(产率为95%,ee为93%)。由花冈的酮中间体制得烯丙基碳酸酯烯丙酸酯前体,后者是由新型的甲酸促进的环扩环反应形成的。
  • Enantioselective Divergent Syntheses of <i>Cephalotaxus</i> Alkaloids: (−)-Cephalotaxine, (−)-Cephalotine B, and (−)-Fortuneicyclidins A and B
    作者:Xian-Tao An、Xiao-Min Ge、Xin-Yu Liu、Yu-Han Yang、Xian-He Zhao、Xiao-Yan Ma、Chao Peng、Yi-Jun Fan、Yong Qin、Chun-An Fan
    DOI:10.1021/jacs.3c01572
    日期:2023.4.26
    block with the tetracyclic A/B/C/D ring system, a concise enantioselective total synthesis of (−)-cephalotaxine starting from readily available homopiperonyl alcohol has been achieved in nine steps with only two column chromatography purifications. Following the tactical introduction of the Meinwald rearrangement, enantioselective divergent syntheses of (−)-cephalotine B with an additional C3–O–C11
    开发了一种新策略,重点关注环 D 的最后阶段不对称组装,它固有地拥有 (−)-头孢紫杉醇 A/B/C/D 环系统中最密集的手性中心和官能团部分,其中设计并探索了一种新型 Rh 催化的叔烯酰胺与烯醇重氮乙酸酯的不对称 (2 + 3) 环化反应,用于对映选择性构建具有独特螺环氮杂-季立构中心的关键环戊烷环 D。基于使用四环 A/B/C/D 环系统快速获得手性功能化结构单元,以现成的高胡椒醇为起始原料,仅用两根色谱柱,通过九个步骤实现了 (−)-头孢紫杉醇的简明对映选择性全合成层析纯化。
  • CN116425760
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 nordeoxyharringtonine cephalotaxine 4′-demethylharringtonine homoharringtonine α-N-oxide cephalotaxine α-N-oxide cephalotaxine α-N-oxide cephalotaxine β-N-oxide (2R,3R,4S,5S)-2,3-bis(tert-butyldiphenylsilyloxy)-cephalotaxan-8-one (2S,3R,5S,7S)-3-methyl-4,17,19-trioxa-11-azahexacyclo[12.7.0.02,7.03,5.07,11.016,20]henicosa-1(21),14,16(20)-triene (2S,6S)-3-methyl-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraene (1S)-2-methoxy-(3atC4,14bt)-1,5,6,8,9,14b-hexahydro-4H-1r,9c-epioxido-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine 1-O-[(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate 2,3,5,6,8,9-hexahydro-1-(pivaloyloxy)-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine Dimethyl 3-(trifluoromethylsulfonyloxy)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,7,13,15(19)-pentaene-7,8-dicarboxylate Alkaloid D Epicephalotaxin Cephalotaxin a u. b (3aα,4aS*,15bβ,15cα)-(+/-)-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>-benzazepine 4-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-3-one (Ξ)-2-methyl-2-(2,2,2-trichloro-ethoxycarbonyloxy)-butyric acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-2-methoxy-1t-(2,2,2-trichloro-ethoxycarbonyloxy)-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-phenyl-(2,2,2-trichloro-ethoxycarbonyloxy)-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester oxalic acid ethyl ester (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-1t-benzyloxycarbonyloxy-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-hydroxy-phenyl-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester [(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-2,6-dihydroxy-6-methylheptanoate (+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine epi-deoxyharringtonine hexa-2t,4t-dienoic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester Dehydrodeoxyhomoharringtonine [(2S,4S,6S)-12-methylsulfanyl-11-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate Omacetaxine mepesuccinate hydrochloride cephalotaxinamide (1R,2S,3aS,14bR)-1,2,3,5,6,8,9,14b-Octahydro-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine-1,2-diol methylfumaric acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 11alpha-Hydroxycephalotaxine